Open

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The purpose is to evaluate if the sonrotoclax in combination with obinutuzumab or rituximab works better and is safe in participants compared to venetoclax plus rituximab for patients with this diagnosis.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

United States (Nationwide), International (Worldwide)

What will be asked of you

Complete physical examination, Blood sample collection, Electrocardiogram to see the electrical activity of your heart, Computed tomography (CT) to locate and measure your disease before starting study treatment

Incentives

Total length of participation:
Estimated treatment duration of 23 months and follow up of 50 months

Looking for Specific Volunteers

Able to participate:

You have been diagnosed with CLL/SLL
You have received ≥ 1 prior therapy for CLL/SLL. For each line of therapy, you must have received at least 2 cycles of this therapy

Not eligible if:

You have known active prolymphocytic leukemia or currently suspected Richter's transformation
You have known central nervous system involvement by CLL/SLL.
You have had a prior autologous stem cell transplant (< 3 months after transplant); or prior CAR-T therapy (< 3 months after cell infusion)
You have a history of confirmed progressive multifocal leukoencephalopathy

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Deborah Stephens
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia, Lymphoma)

IRB Number

25-1026

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.